J. Goldman & Co’s Acceleron Pharma XLRN Stock Holding History

J. Goldman & Co’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-17,561	Closed	-$931K	–	378
2019 Q4	$931K	Buy	+17,561	New	+$801K	0.07%	189

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

J. Goldman & Co's XLRN Position: Q1 2020 in Review

J. Goldman & Co sold out of Acceleron Pharma (XLRN) in Q1 2020, closing a stake of 17,561 shares — an estimated $931K sold.

J. Goldman & Co first reported a position in XLRN in Q4 2019 and held it in 1 quarter. The position peaked at $931K in Q4 2019. 217 funds tracked by Wall St. Rank hold XLRN as of Q1 2020.

J. Goldman & Co reported no remaining Acceleron Pharma position as of Q1 2020 after selling out during the quarter.
J. Goldman & Co sold 17,561 Acceleron Pharma shares in Q1 2020, an estimated $931K.
J. Goldman & Co first reported a position in Acceleron Pharma in Q4 2019 and held it in 1 quarter.
J. Goldman & Co's Acceleron Pharma position peaked at $931K in Q4 2019.
217 funds tracked by Wall St. Rank held Acceleron Pharma as of Q1 2020.

Based on J. Goldman & Co's 13F filing for Q1 2020, filed 15 May 2020.